Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.50
Bid: 12.00
Ask: 13.00
Change: 0.25 (2.04%)
Spread: 1.00 (8.333%)
Open: 12.25
High: 12.50
Low: 12.25
Prev. Close: 12.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Angle upbeat on recent cancer research results

Fri, 21st Jun 2019 15:26

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.The AIM-traded firm said the expression of the protein PD-L1 in cancer cells was of particular importance as PD-L1, and the PD-1 protein to which it binds, were the key targets for leading immunotherapy drugs, with revenues forecast to exceed $20bn in 2019.It said immunotherapy drugs could be "very effective" for some patients, however, typically only between 20% and 30% of patients would respond.That meant it was "crucial" to be able to accurately identify which patients, both to reduce the patient's exposure to unnecessary drug toxicity and to reduce unnecessary healthcare expenditure, given such treatment could cost around $0.15m per patient each year, and only a minority of patients would benefit.The company said the research by UKE, undertaken using Parsortix over a three-year period and published in the peer-reviewed medical journal 'Cancers', showed that in a head-to-head comparison of 97 lung cancer patients, Parsortix was able to detect circulating tumor cells (CTCs) in nearly twice as many patients as the leading competing system.Additionally, the research showed that the PD-L1 expression in a tissue biopsy - the current standard of care, which Angle described as "invasive and expensive" - did not always reflect the heterogeneity of PD-L1 expression in the cancer of Stage IV NSCLC patients with multiple tumor sites, meaning a Parsortix CTC liquid biopsy could therefore provide more comprehensive information.A longitudinal investigation using Parsortix in NSCLC patients being treated with immunotherapy drugs 'pembrolizumab' (Keytruda), 'nivolumab' (Opdivo) or 'atezolizumab' (Tecentriq) over multiple time points investigated the changes in PD-L1 positive and negative circulating tumor cells.In all the NSCLC patients that developed resistance to those immunotherapies, an increase in PD-L1+ CTCs was identified compared to earlier time points.Angle said UKE's success in using Parsortix for PD-L1 analysis in NSCLC was consistent with work previously published demonstrating the use of Parsortix for PD-L1 analysis in head and neck squamous cell carcinoma (HNSCC), with the board anticipating that Parsortix could be used for PD-L1 analysis in multiple other cancer types.It said Keytruda, for example, was a broad spectrum anti-cancer drug and had already been approved for 15 cancers and 10 tumor types.Tissue biopsy in the lung, both for lung cancer and as a common metastatic site, was described by the company as "challenging", carrying significant risk with up to 24% of patients experiencing serious complications and up to 1% resulting in death.Additionally, it said the tissue biopsy is expensive, impractical for repeat testing, with a "significant proportion" of biopsies failing to provide sufficient quality or quantity of tissue for accurate analysis.The Parsortix CTC liquid biopsy had the potential to address those limitations through a simple blood test.Angle said the ctDNA liquid biopsy approach - fragments of DNA from dead cancer cells - used by a number of large scale laboratories could analyse PD-L1, as that was a protein expression on the cancer cells.Lung cancer had the highest incidence and mortality rate of all cancers, Angle noted.The board said it believed there was an opportunity to build on the work undertaken to provide services to pharmaceutical drug trials in determining likely patient responders, and as a companion diagnostic to assess which patients were likely to respond to particular immunotherapies."The ability to identify which patients will respond to PD-L1/PD-1 immunotherapies and to assess response to these drugs during treatment, is a major unmet medical need," said Angle founder and chief executive officer Andrew Newland."The Parsortix system addresses key shortcomings in alternative approaches offering the potential for routine liquid biopsies through a simple blood test."
More News
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more
11 Dec 2023 20:44

TRADING UPDATES: Ondine Biomedical raises GBP2.9 million via placing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Dec 2023 11:50

IN BRIEF: Angle launches diagnostic kit at cancer symposium

Angle PLC - Surrey, England-based medical diagnostics company - Launches its Portrait Plus CTC staining kit at the San Antonio Breast Cancer Symposium, following "extensive" development, optimisation and validation of the kit. Explains that the kit is read-to-use, and designed for the dentification, characterisation and enumeration of epithelial and mesenchymal cancer cells. This includes those undergoing epithelial-to-mesenchymal transition.

Read more
9 Nov 2023 14:29

Angle says build up of revenue slower than hoped; launches test

(Alliance News) - Angle PLC on Thursday said it expects revenue in 2023 to more than double from 2022 as it announced the launch of a new test aimed to support cancer therapy studies.

Read more
25 Oct 2023 17:28

TRADING UPDATES: Franchise Brands trading in line; Tribe secures loan

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
3 Oct 2023 13:02

Angle hails study which shows Parsortix outperforming lab standard

(Alliance News) - Angle PLC on Tuesday touted the publication of a study by researchers at the University of Tubingen in Germany, which showed that its Parsortix system outperformed the current laboratory standard for disseminated tumour cell harvest.

Read more
14 Sep 2023 09:22

LONDON BROKER RATINGS: JPMorgan ups Rio Tinto; Redburn likes Carnival

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.